If you have been following @buyersstrike on Twitter, you might see the occasional tweet about Neuralstem (CUR). Over here at BuyersStrike! HQ we find Neuralstem to be absolutely incredible. It takes a lot to stand above the crowd in the current world of bio-dreck mania. So, what makes this 2006 direct to the OTC-BB company so fascinating?
Well, the thing that makes this company so incredibly amazing (if they can successfully patent and commercialize) could make the company worth more than Apple, Tesla, Google, combined! Yes, more than all of them. Intrigued? Read on….
CUR is a plaything of Bedminster, NJ based bucket shop T.R. Winston. Read the FINRA Broker Check report on T.R. Winston here. But being associated with a schlock shop is not what makes Neuralstem so incredible.
CUR is loved by Brean Capital‘s wretched Jonathan Aschoff. But Jonathan Aschoff likes lots of penny stock garbage dressed in bio-tech bubble clothes. He shamelessly touts Joe Podoloski’s RPRX, the stock promoting goons at INO, the reborn penny scam OHRP, CTSO, and many more. So having a sell side whore like Asshoff strap on his kneepads for the company is not what makes Neuralstem so incredible.
CUR‘s CEO, Richard Garr, is no stranger to controversy. A little over a year ago, in January 2014, while raising money through the above named bucket shop, TR Winston, Garr, in an (at best) ethically dubious move, tweeted about a patient in the Neuralstem ALS clinical trial. Crain’s NY writer Aaron Elstein, in an excellent piece available here, investigated the tweet activity and the TR Winston – Neuralstem connection. Yet this is still not what makes Neuralstem so incredible.
CUR announced today highly misleading results of that very same, incredibly poorly designed, ALS clinical trial. Read their spin-laden bullshit press release here. While Neuralstem tries valiantly to obfuscate the real results by offering a bizarre post-hoc grouping of patients, TheStreet.com’s Adam Feuerstein sees through CUR’s bullshit in an article available here. Lots of companies put out bullshit press releases, so that is not what makes Neuralstem so incredible.
But hidden in that press release is the gem that makes CUR so incredible. Here is a direct quote, emphasis ours:
GERMANTOWN, Md., March 12, 2015 /PRNewswire/…
The average ALSFRS score for responders at 9 months after treatment was 37. Non-responders scored an average of 14. These scores represent 93%, versus 35%, of the baseline score retained, respectively, by the responders versus non-responders at 9 months, which is a statistically significant difference.
Keen observers of Neuralstem, or just anyone who can use Yahoo! Finance, probably recall that in August of last year, CUR announced that the final patient in the Phase 2 ALS trial was treated. The relevant section is quoted below, emphasis ours:
GERMANTOWN, Md., Aug. 4, 2014 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).
Using a little advanced math, lets count 9 months forward from August 4th. September, October, November, December, January, February, March, April, and May. How can the company report 9 month trial results in early March 2015 if the last patient was only treated in early August 2014? The 9 month results cannot possibly have been compiled yet.
Neuralstem might not have cured ALS, but they just may have solved the mystery of time travel! Imagine the possibilities. And that, dear readers, is what makes CUR truly incredible!